Weekly research, verified before it publishes
One free report a week, on one under-radar public equity — picked and written by an automated research process, verified against real financial data before publication. Research process output, not investment advice, and never a buy, sell or hold call.
Reports cover small and micro-cap companies, which can be illiquid and can lose most or all of their value.
Outlook Therapeutics: substantial doubt about going concern after a $55.0M offering
The company discloses substantial doubt about its ability to continue as a going concern and estimates its cash will last into the second quarter of calendar year 2027.
Meridian Signal Score: the unweighted average of the 1-10 factor scores that could be computed from the figures in this report (Growth, Valuation, Balance sheet, Stability, Insider buying) - not a proprietary black-box model, and not a recommendation to buy, sell, or hold. 3 of 5 factors scored this week. Not scored (no meaningful input): growth, valuation.
Going-concern doubt disclosed by the company
From its 10-Q filed 2026-08-18: "There is substantial doubt about our ability to continue as a going concern." Under US accounting rules that wording is used when conditions indicate the company probably cannot meet its obligations within a year without new financing or other action.
Negative shareholders' equity (-$10.4M)
Liabilities exceed assets on the latest balance sheet, so book-value and return-on-equity ratios are not meaningful.
Share count is 4.5x its 2025-09-30 level
243.4M shares outstanding on 2026-08-14 versus 53.9M on 2025-09-30, per the company's 10-Q filed 2026-08-18. Extra shares come from offerings, conversions or stock compensation and shrink each existing holder's ownership.
Fell 93% from peak to trough in the past ~18 months
Largest peak-to-trough decline in the price history on file and has not recovered.
Late-filing notice: NT 10-Q on 2026-08-17
From its NT 10-Q filed 2026-08-17: "As a result of the Company’s size and recent turnover in its finance department, as well as the devotion of significant time and resources by the Company’s finance personnel in connection with the Company’s public offering that closed on August 14, 2026, the Company has had limited available internal accounting and finance personnel to assist with review and preparation of its financial statements to ensure adequate disclosure of the financial information required to be included in the Form 10-Q."
Company states its cash lasts into the second quarter of calendar year 2027
From its 10-Q filed 2026-08-18: "We estimate that our cash and cash equivalents as of June 30, 2026, together with $51.1 million in net proceeds from our August 2026 Offering, will only be sufficient to fund our operations into the second quarter of calendar year 2027." That is about 3.1 quarters from the report date and depends on money raised after the 2026-06-30 balance sheet, which on its own showed $11.2M of cash against $56.2M of trailing-12-month operating cash burn (0.8 quarters). A company's own runway estimate is a forecast, not a guarantee.
Current ratio of 0.81
Short-term liabilities exceed short-term assets, which leaves little cushion if funding is delayed.
Loss-making: net loss of $61.1M (trailing 12 months)
Earnings-based multiples such as P/E are not meaningful while earnings are negative.
Extreme volatility: 175% annualized
Based on the last 90 trading days; for comparison, the S&P 500 typically runs around 15-20%.
14.4% of shares are sold short (1.5 days of average volume to cover)
A high short interest means a meaningful group of traders is betting on a decline.
August offering: $55.0M sold at $0.99 per share, with warrants
424B5 filed 2026-08-14: 55.6M shares at $0.99, warrants on 55.6M more shares exercisable at $1.10, $55.0M gross, company-stated net proceeds of $51.1M. The prospectus gives the last reported sale price as $1.10 on 2026-08-12, so the price for a share plus a warrant was 10% below it.
Insiders bought $368K apart from company offerings
6 purchases by 4 insiders and no sales (transactions on file, 2025-05-27 to 2026-08-14). This excludes the purchases the company's 8-K says were made inside company offerings, shown separately.
Trades below its 50-day and 200-day averages
Price $0.69 versus $0.93 (50-day) and $0.81 (200-day).
Insiders took part in company offerings (11.3M shares)
4 purchases by 3 insiders (11.3M shares) match purchases inside a company offering: named in its filings, or made in the offering window at the offering price. Buying in an offering at its price is not an open-market vote on the stock, so it is not counted as insider buying.